IN8bio (INAB) Projected to Post Quarterly Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, March 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. On average, analysts expect IN8bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IN8bio Trading Down 1.6 %

NASDAQ:INAB opened at $0.17 on Tuesday. IN8bio has a 52 week low of $0.13 and a 52 week high of $1.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm’s fifty day moving average is $0.20 and its 200-day moving average is $0.26. The firm has a market cap of $13.55 million, a P/E ratio of -0.22 and a beta of 0.23.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price target on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a report on Friday, March 14th.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.